Health24.com | Could AI spot which coronavirus patients are at possible risk of severe disease?

An international team has designed a computer programme that predicts with up to 80% accuracy which coronavirus patients will develop serious respiratory disease.

Developed by US and Chinese researchers, the artificial intelligence (AI) programme has been tested at two hospitals in China with 53 patients who were diagnosed in January with Covid-19. The new tool is considered experimental and is now in testing.

The aim is to help doctors make the best use of limited resources, by identifying early on which patients will likely need hospital beds and which can be sent home for self-care. In theory, it could also help direct administration of aggressive treatment even in the initial absence of severe symptoms.

“Of those who have symptoms, 80% – maybe up to 85% – will have mild disease; around 15% to 17% will have severe disease and need to be hospitalised; and a further 3% to 5% will need intensive care, usually due to Acute Respiratory Distress Syndrome [ARDS],” said study co-author Dr Megan Coffee.

Covid-19 starts mildly in everyone

She’s a clinical assistant professor of infectious disease and immunology at NYU Grossman School of Medicine in New York City.

ARDS is a potentially deadly condition in which fluid leaks into the lungs, making breathing increasingly difficult. Coffee said at least two-thirds of Covid-19 patients who go on to need treatment in a hospital intensive care unit develop ARDS, which is the “underlying process leading to death in many of the cases”.

But Coffee noted that Covid-19 starts mildly in everyone, with a cough, fever and upset stomach.

“A small percentage will go on, five to 10 days later, to develop very severe disease and some will require intubation. It’s not always clear who,” she said. “Sometimes someone in their 30s with no medical history has more severe disease than someone in their 70s with multiple medical problems.”

So the goal, Coffee said, was to develop an artificial intelligence version of a “master clinician” – meaning a very experienced doctor dealing with a well-known disease.

Working with researchers at two hospitals in Wenzhou, China, the NYU team devised a computer model based on the kind of “predictive analytics” used to forecast stock market activity and voting patterns.

Slight elevations in a liver enzyme

They fed it relevant patient information, such as results of lung scans and blood tests, muscle ache and fever patterns, immune responses, age and gender.

To their surprise, researchers found that the factors most clinicians would likely focus on – such as lung status, age and gender – were not helpful in predicting outcomes.

So what was?

The most accurate predictors were slight elevations in a liver enzyme called alanine aminotransferase (ALT); deep muscle aches; and higher levels of haemoglobin, the protein that facilitates blood transport of oxygen throughout the body.

“That’s the value of this approach,” Coffee said, “to look for what we, as clinicians, might not notice.”

While the programme needs to be validated on larger populations, she said it would be easy to roll out if future testing finds similar accuracy.

Tested in a very small sample

The tool could prove “very useful”, said Dr Maria Luisa Alcaide, a fellow with the Infectious Diseases Society of America who reviewed the findings.

“What’s happening with Covid-19 is that cases have significantly increased to the point where some hospitals’ ICUs are overwhelmed,” she noted. “And for reasons that are not well-understood, not everyone who gets very sick fits the profile of an older person with underlying conditions.”

The better doctors are able to predict those who will, the more carefully they could track them and their care, said Alcaide, who is also an associate professor of infectious diseases at the University of Miami.

But the method has been tested only in a very small sample of patients, and hundreds of thousands are now infected, she pointed out.

“It’s unlikely that this small sample is representative of all Covid-19 patients,” Alcaide said. Some of these predictors may turn out to be important. But we just don’t know yet. Other markers may turn out to be more important. So, this really needs to be validated with more patients.”

The findings are reported online in the issue of the journal Computers, Materials & Continua.

READ | Many approved drugs may hold promise against coronavirus

READ | Pink eye could be a less common symptom of the new coronavirus

READ | More evidence that coronavirus survivors’ blood could help very ill patients

Image credit: Getty Images

Share Button

Coronavirus: Should the UK use drones to disinfect public spaces?

A group is calling for a change in regulation so drones can spray disinfectant in public places

Share Button

Understanding how the protein tau moves between neurons yields insight into possible treatments for neurodegenerative diseases

In the fight against neurodegenerative diseases such as frontotemporal dementia, Alzheimer’s and Chronic Traumatic Encephalopathy, the tau protein is a major culprit. Found abundantly in our brain cells, tau is normally a team player — it maintains structure and stability within neurons, and it helps with transport of nutrients from one part of the cell to another.

All that changes when tau misfolds. It becomes sticky and insoluble, aggregating and forming neurofibrillary tangles within neurons, disrupting their function and ultimately killing them. Worse, it probably can take relatively few misfolded tau proteins from one cell to turn its neighbors into malfunctioning, dying brain cells.

“This abnormal form of tau starts to spread from cell to cell,” said UC Santa Barbara neuroscientist Kenneth S. Kosik. “It’s reminiscent of a serious problem that’s known in biology, called prion diseases, such as mad cow disease.”

Importantly, unlike true prion diseases, which are spread by contact with infected tissue or bodily fluid, prion-like diseases such as frontotemporal dementia and other tauopathies aren’t contagious — they can’t be spread from person to person or by coming into contact with infected tissue. However, the replication is eerily familiar: A misfolded tau protein gets out of a cell and gets taken up by a normal neighboring cell. It then acts as a template in that cell, Kosik explained, which subsequently produces misfolded tau. Over and over again, the cells produce and secrete the toxic knockoff version of tau until whole regions of the brain are affected, which over time will rob a person of their cognitive and physical functions.

What if the spread could be contained? If caught early enough, controlling the proliferation of pathological tau could keep the neurodegenerative disease from progressing, and give the patient a shot at a normal life. But in order to do that, scientists first have to understand how the protein gets around.

In a paper published in the journal Nature, Kosik and his team have uncovered one such mechanism by which tau travels from neuron to neuron. Not only does it shed light on the extensively studied but rather poorly understood tau propagation in neurodegenerative disease, it hints at a way to control the spread of pathological tau.

“The discovery of a mechanism by which tau transits from cell to cell provides a clue that will open up a deep structural approach to the design molecules that can prevent tau spread,” said Kosik, who is the Harriman Professor of Neuroscience Research in UC Santa Barbara’s Department of Molecular, Cellular, and Developmental Biology.

The major player in this mechanism of uptake and spread, it turns out, is the low-density lipoprotein called LRP1 (low density lipoprotein receptor-related protein 1). It’s located on the brain cell membrane and is involved is several biological processes, among them helping the neuron take in cholesterol, which is used as part of cellular structure.

LRP1, the researchers discovered, takes up tau in neighboring cells after it escapes from a cell into the extra-cellular space. One of several low density lipoprotein receptors, LRP1 was singled out by process of elimination: By systematically inhibiting the expression of each of the members of this family via CRISPRi technology, and exposing them to tau, the researchers determined that genetic silencing of LRP1 effectively inhibited tau uptake.

“This protein is an interesting one in its own right because it’s a little bit like an extracellular trash can,” Kosik said. “It doesn’t just pick up tau; if there’s other rubbish out there, it also picks it up.”

But what about tau is LRP1 recognizing? Digging deeper, the scientists found that a stretch of the amino acid lysine on the tau protein acts as kind of the secret handshake that opens the doors to the neuron.

“So these are all clues,” Kosik said.

Stopping the Spread

“Since our cellular work showed that tau can interact with the cell-surface receptor LRP1 and that this causes tau’s endocytosis, our hypothesis was that if we reduce LRP1 expression in the mice we should reduce the ability for neighboring neurons to take up tau,” explained the study’s lead author, postdoctoral researcher Jennifer Rauch.

To back their in-vitro studies, the researchers injected tau into mice, some of which had their LRP1 genes downregulated by a LRP1 suppressor RNA. The tau proteins were bound by a small string of amino acids to a green fluorescent protein to help the scientists observe tau after it was injected.

“As soon as this construct is in a cell, the amino acid connector gets cut, and the fluorescent protein and tau separate from each other,” Kosik explained. What they found was that in the animals with normal LRP1, the tau had a tendency to spread; in the LRP1-suppressed mice, the protein stayed put, greatly reducing the likelihood that it would be taken up and replicated by other, normal neurons. “This is the first time we’ve seen the complete obliteration of tau spread,” he said.

“When we reduce LRP1 expression, we see reduced tau spread in the animals,” said Rauch, who has previously worked on the role of heparan sulphate proteoglycans on tau uptake. She pointed out a recent study that included Kosik and graduate student Juliana Acost-Uribe that described a patient with a severe genetic form of early-onset Alzheimers’s but was spared getting the disease due to a second mutation that appeared to prevent tau spread. The team is keen to learn how this patient’s second mutation might prevent tau spread possibly by interacting with LRP1.

“Next,” Rauch said, “we are focusing on trying to decipher the interface of the tau-LRP1 interaction and understand if this could be a drug-able target.”

Share Button

New CT scoring criteria for timely diagnosis, treatment of coronavirus disease (COVID-19)

Updated CT scoring criteria that considers lobe involvement, as well as changes in CT findings, could quantitatively and accurately evaluate the progression of coronavirus disease (COVID-19) pneumonia, according to an open-access article in the American Journal of Roentgenology (AJR).

“The earlier that COVID-19 is diagnosed and treated, the shorter the time to disease resolution and the lower the highest and last CT scores are,” concluded lead author Guoquan Huang of Wuhu Second People’s Hospital in China.

Assigning CT scores to 25 patients according to CT findings and lung involvement, Huang and colleagues recorded the time from symptom onset to diagnosis and treatment for each patient. Patients with COVID-19 were divided into two groups: (patients for whom this interval was ? 3 days) and group 2 (those for whom the interval was > 3 days).

Using a Lorentzian line-shape curve to show the variation tendency during treatment, the fitted tendency curves for group 1 and group 2 were significantly different. Peak points showed that the estimated highest CT score was 10 and 16 for each group, respectively, and the time to disease resolution was 6 and 13 days, respectively.

The Mann-Whitney test showed that the last CT scores were lower for group 1 than for group 2 (p = 0.025), although the chi-square test found no difference in age and sex between the groups. The time from symptom onset to diagnosis and treatment had a positive correlation with the time to disease resolution (r = 0.93; p = 0.000), as well as with the highest CT score (r = 0.83; p = 0.006).

“Sequential chest CT examinations enable qualitative investigation of alterations in COVID-19 infection during the course of treatment,” Huang explained.

Because previously proposed CT scoring criteria regarding lobe involvement gave no consideration to changes in CT features (i.e., the change from observation of GGO to a crazy-paving pattern and then consolidation), Huang et al. suggest that such a rubric is not sufficiently accurate to assess the progression of pneumonia.

“In the present study,” wrote Huang, “we propose a new version of CT scoring criteria that considers both lobe involvement and changes in CT findings, in an attempt to more comprehensively evaluate COVID-19 pneumonia on sequential chest CT examinations.”

Story Source:

Materials provided by American Roentgen Ray Society. Note: Content may be edited for style and length.

Share Button

Homo naledi juvenile remains offers clues to how our ancestors grew up

A partial skeleton of Homo naledi represents a rare case of an immature individual, shedding light on the evolution of growth and development in human ancestry, according to a study published April 1, 2020 in the open-access journal PLOS ONE by Debra Bolter of Modesto Junior College in California and the University of the Witwatersrand, Johannesburg, and colleagues.

Much research has gone into the evolution of ancient hominins — human relatives and ancestors — but little is known about their growth and development. Most hominin fossils represent adult individuals, and remains of developmentally young hominins are rare. This has left a gap in our understanding of how our ancient relatives grew from young into adults, and how modern human growth patterns evolved.

In this study, Bolter and colleagues examined fossils from the Dinaledi Chamber of the Rising Star Cave System in South Africa. This site is famous for providing abundant remains of the hominin Homo naledi, including individuals ranging from infants to adult. These fossils date to the late Middle Pleistocene, between 335,000 and 226,000 years ago, possibly overlapping in time with the earliest members of our own species. The team identified a collection of arm and leg bones and a partial jaw as the remains of a single young individual designated DH7.

The bones and teeth of DH7 were not fully developed and display a mixture of maturity patterns seen in modern humans and earlier hominins. DH7 is estimated to be similar in its developmental stage to immature specimens of other fossil hominins between 8-11 years old at death. The authors note, however, that if Homo naledi had a slower growth rate like modern humans, DH7 might have been as old as 15. Further study is needed to assess how Homo naledi grew and where it fits into the evolution of human growth and development.

Bolter adds: The rare juvenile Homo naledi partial skeleton will shed light on whether this extinct species is more human-like in its development, or more primitive. The findings help reconstruct the selective pressures that shaped extended maturity in our own species.

Story Source:

Materials provided by PLOS. Note: Content may be edited for style and length.

Share Button

Health24.com | Many approved drugs may hold promise against coronavirus

Two new studies each suggest that dozens of drugs already approved for use in the United States may prove effective against the new coronavirus.

“Repurposing these FDA-approved drugs could be a fast way to get treatment to patients who otherwise have no option,” explained the co-author of one of the studies, Dr Hesham Sadek. He’s professor in the departments of internal medicine, molecular biology and biophysics at UT Southwestern Medical Center, in Houston.

However, experts stressed that this research is still in its early stages, so people shouldn’t try any of the drugs now to prevent or treat Covid-19.

Right now, “there is no specific medicine recommended to prevent or treat the new coronavirus,” according to the World Health Organization (WHO). “Some specific treatments are under investigation, and will be tested through clinical trials,” the WHO said, according to the Washington Post.

It could take months

As Covid-19, the illness caused by the new coronavirus, sickens hundreds of thousands worldwide, the race is on to find a drug that might help save severely ill patients.

But even with rapid government approval, it could take months to develop new drugs from scratch that might be effective against the virus, Sadek explained in a UT Southwestern news release.

That led his team to conduct computer modelling studies on certain drugs already approved by the US Food and Drug Administration, to assess their potential in combating the coronavirus.

The results showed that the most promising drugs include several antiviral drugs – including Darunavir, Nelfinavir, and Saquinavir – and several other types of drugs, including the ACE inhibitor Moexipril; the chemotherapy drugs Daunorubicin and Mitoxantrone; the painkiller Metamizole; the antihistamine Bepotastine; and the antimalarial drug Atovaquone.

Another promising candidate is the cholesterol-lowering statin rosuvastatin, which is sold under the brand name Crestor. It’s already taken by millions of patients around the world to lower their cholesterol, is safe, inexpensive and readily available, Sadek noted.

The results were published on a pre-print server called ChemRxiv; they have not yet been subject to peer review.

Findings submitted to journal

Also, because this study was completely computer-based, their effectiveness against the new coronavirus remains theoretical. Only further research could confirm their effectiveness prior to use in actual patients, the Houston researchers stressed.

A second study was led by biologist Nevan Krogan of the University of California, San Francisco. It found that nearly 70 drugs – some already approved, some still experimental – might prove effective against the novel coronavirus.

Krogan’s group has so far only published their findings on the website bioRxiv, and the findings have been submitted to a medical journal, The New York Times reported.

In this effort, the researchers took a deep dive into the genetic makeup of the novel coronavirus, focusing on key proteins the virus uses to hijack the genetic machinery of a host human cell. The coronavirus uses the cell’s protein to then manufacture millions of copies of itself.

Krogan’s team searched for drugs that target the same human cellular proteins that the virus also targets during its invasion of the host cell. They uncovered 24 drugs already approved by the FDA for use against a wide range of diseases, such as cancer, Parkinson’s disease and high blood pressure.

Also on the list were certain antibiotics; metformin, the go-to drug for type 2 diabetes; the schizophrenia drug haloperidol; and the malaria drug chloroquine.

Well-run trials essential

The latter drug gained prominence after President Donald Trump suggested at a recent news briefing that it might work against Covid-19. But Dr Anthony Fauci, the director of the US National Institute of Allergy and Infectious Diseases, quickly qualified that statement, saying there was only “anecdotal evidence” that chloroquine might work against the new coronavirus.

He stressed that only well-run trials could prove effectiveness; such trials are being planned by the WHO and the state of New York, the Times noted.

And there’s a potentially lethal downside to trying any of the aforementioned drugs on your own, experts warned.

That danger was illustrated in a tragedy occurring just this week. According to the Washington Post, one Arizona couple in their 60s took matters into their own hands after watching Trump’s news briefing. Buoyed by his words on chloroquine, the couple self-treated with the drug – which they had previously used to clean their koi pond.

After mixing the chemical with soda and drinking it, they each felt dizzy and started vomiting. The husband died at the hospital, and the wife is still under critical care in the hospital, the Post reported.

A number of ongoing efforts

So, don’t “self-medicate” with any of these drugs until better research is done. Krogan’s collaborators at the Icahn School of Medicine at Mount Sinai in New York City and the Pasteur Institute in Paris have already begun testing the mettle of 22 compounds on their list against the coronavirus, under laboratory conditions, the Times said.

The new coronavirus first appeared in China in late 2019. As of 23 March, there had been nearly 335 000 cases of Covid-19 and nearly 14 700 deaths worldwide, according to the WHO.

There are a number of ongoing efforts to develop effective treatments and vaccines, but no clear treatment or prevention strategies currently exist.

READ | Doctors warned against prescribing unproven medication for Covid-19

READ | Odds of hospitalisation, death with coronavirus rise steadily with age

READ | Could gene mutations explain coronavirus cases in the young?

Image credit: Getty Images

Share Button

Writing From the Void

Normally when I want to write a new blog post, I take a few minutes to tune into an idea, and then it begins to flow into writing. Getting an idea involves listening with my inner senses, as if I’m scanning some electromagnetic field for signal matches. When I discover a match, I can lock onto it, and then it’s rather easy to let the idea flow through into words.

The idea comes through as energy that I perceive as oscillations in my thoughts, and it combines with memories and other knowledge as I write. So first I get an initial sense of the idea in my mind, but it’s really through the process of writing that I grow into a full understanding of what’s being expressed.

So I don’t really know what article I’m writing till it’s written. Sometimes I can only see the beginning third of it or so, and the rest comes into view after I’ve written part of it.

I also get ideas from other sources, like people making suggestions. But the best articles that people appreciate most are usually writing with the process of scanning for inspiration and inviting it to flow through. I’ve shared more about this process in the article How I Write.

An interesting thing that happened today was that when I tried to summon an article idea, nothing actually came through. I sensed that the field of energy that I normally gather ideas from had gone silent. This happens now and then, and usually what I do is just assume that I don’t need to write anything at that particular time. I figure there’s no message to deliver. So I don’t write anything on those days, or I try again later in the day.

Usually when nothing comes through, it’s because there’s some inspiration to be followed in a different direction that doesn’t involve writing. I have to broaden my idea scanning to include more frequencies, not just the ones in the writing ideas spectrum. Then I usually notice that I’m pulled towards an idea for what to do next. It could be a business idea or a personal idea. When I sense the energy signature of an aligned idea, I like to flow into it with action right away.

Today, however, when I did the broader scanning and invitation process, still nothing came through in any direction. That seemed odd, but it does happen now and then too. So I decided to just sit with that for a while. I sat and did nothing and waited. If the inspiration field is silent, perhaps doing nothing for a while is the right course of action.

Eventually I got the idea to try an experiment, which was to write in a different way. Instead of waiting for some signal to come through, I popped open my journal and decided to write from within the space of nothingness. No special inspiration. No ideas coming through. Just write from the void. You’re reading that journal entry now.

I began thinking about how many writers write every day whether they feel inspired or not. I almost always wait for inspiration. But what happens when my timing and the timing of the inspiration don’t coincide? That’s a concern for this year because of my one-year daily blogging commitment. Can I expect that I’ll always be able to write from inspiration as I have in years past if I’m doing this more frequently than ever?

I’ve gone to the well of ideas so many times before, and the ideas feel like they already exist in some form, like they’re grapes growing on a vine, and I’m plucking a grape off the vine. Then my assignment is to consume and digest that grape and turn it into a new article. The vine still feels like it has an abundance of grapes, but I also feel that perhaps it’s time to explore some other idea space and leave the grapes to others sometimes.

These signals often feel like they’re coming from other people. It feels like I’m tuning into what someone out there wants helps with, and then I write an article for that person. I often feel like I’m tuned into the energy of an individual or perhaps a small group of people with similar desires when I write new articles.

Something I value about this daily blogging challenge, however, is the opportunity to explore other aspects of writing and self-expression that I may not have considered as much. I’ve leaned on a certain mode for getting ideas for so long that it’s second nature to me. And so it feels a little too easy to keep leaning on that skill.

Today is my 100th day in a row of blogging (I started on December 24th). So I don’t have any doubt that I can keep this up for a full year. But writing every day with the same approach I’ve been using feels like hanging out on a plateau. I think what I’ve been sensing lately, especially with respect to having my own wake-up call, is a desire to move beyond this familiar and comfortable mode of writing. It’s easy. It’s abundant. I can write that way all day and produce an infinite stream of content. But I’m not seeing much inner growth in repeating the same approach day after day.

I can also switch media like doing video and audio, but I’ve done that as well, and I still summon ideas using the same approach, so it doesn’t really feel new. It only felt new up to the point where I grew just as comfortable creating through other media, but then it’s pretty much the same.

I look around and see a world full of self-expression. Every day people are cranking out more and more content and consuming the content of others. While initially I found that fascinating and fun to participate in, now it feels a bit too boring and predictable if I keep using the same approach. It’s an infinite game, but it feels overly bounded to me.

I’m going to continue the daily blogging challenge, but I want to explore other ways of doing this going forward, especially in terms of how I generate ideas. It’s appealing to seek ideas in frequency ranges where I’m not used to scanning. I’m really not sure what form that will take or what it will look like. And I really don’t even know where to begin. I just sense that it’s time to mix things up.

This isn’t an April Fools’ joke by the way. I thought about doing one, but that also feels a bit cliché, and if you can believe this, I’m actually still getting emails every month from people falling for the one from 2011. It’s been eye-opening to discover just how many people would like to be enslaved. So I have to consider how a playful joke may affect my email inbox for the next decade or so.

Share Button

Health24.com | How to keep housebound kids busy during a pandemic

If you and the kids are staying home to avoid the coronavirus, the American Academy of Pediatrics (AAP) offers this advice to help you make the best of the situation.

Make a plan. Talk to your children about daily structure, dealing with stress, and when you’ll take breaks from remote work and schoolwork.

Ask teachers about online and offline educational activities for your kids. School districts may be able to help connect low-income families to free Wi-Fi or devices.

Use social media to check in with neighbours, friends and loved ones. If your kids miss their school friends or relatives, try video chats or social media to stay in touch.

Expect to make adjustments

Decide how much time kids can play video games online with friends, and where their devices will charge at night. Challenge your children to practice “tech self-control” and turn off the TV, tablet or video game themselves, rather than having you remind them.

If you work from home, expect to make adjustments. But it’s also an opportunity. Encouraging imaginative “work” play, for instance, could be a way to have a “take your child to work day” at home.

Podcasts and audiobooks can keep your children’s minds engaged while you work or do other tasks.

Do offline activities that help your family relax and communicate. Take walks outside, play board games, read together, have family dance parties and do activities that spark your children’s interest.

Share your worries

Get ideas from other families and share your ideas with them.

Create opportunities for family members to share their worries, and monitor your own technology use. If you focus too much on the news or social media and stress out, your kids will notice. Take a break to protect your mental health.

Be sure that everyone gets the sleep, physical activity, reading, reflective downtime and family connection time they need.

READ | Looking after your mental health during the coronavirus crisis

READ | A parent’s guide to fighting coronavirus stress

READ | How could you calm your child’s coronavirus fears?

Image credit: Aaron Burden, Unsplash

Share Button

Coronavirus: NHS 111 has 1.7 million queries in 15 days

Most of the queries, from people flagging potential symptoms, were handled online.

Share Button

Coronavirus: Potential drug treatment starts UK trials

A drug that could treat patients with coronavirus is to undergo clinical trials at 15 NHS centres.

Share Button